Treatment of Latent Autoimmune Diabetes of the Adult (NCT01140438) | Clinical Trial Compass
CompletedNot Applicable
Treatment of Latent Autoimmune Diabetes of the Adult
Norway64 participantsStarted 2009-03
Plain-language summary
The purpose of the study is to clarify whether patients classified as Latent autoimmune diabetes of the adult (LADA) benefit from early treatment with insulin added to per oral treatment and lifestyle measures.
Who can participate
Age range30 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Diabetes diagnosed during 0-3 years before entering the study.
* Age \> or equal to 30 years \< or equal to 75 years
* anti-GAD positivity
* fasting C-peptide \> or equal to 0,3 ng/ml
* no need for insulin treatment by clinical judgement for at least 3 months following the diagnosis of diabetes.
* HbA1c \> 15 % above the upper limit of normal
Exclusion Criteria:
* Renal insufficiency (plasma creatinine \> 150 mol/L)
* Severe retinopathy (proliferative or pre-proliferative)
* Severe cardiac disease (NYHA III-IV)
* Chronic severe illness judged by the investigator
* Females of reproductive age who wish to become pregnant during the study
What they're measuring
1
insulin secretion
Timeframe: 2 years
Trial details
NCT IDNCT01140438
SponsorNorwegian University of Science and Technology